In Brief: Schering-Plough
This article was originally published in The Tan Sheet
Executive Summary
Schering-Plough: Submits April 30 comments on FDA's March 4 proposed rule on interchangeable terms for OTC labels ("The Tan Sheet" March 4, In Brief) requesting that the term "podiatrist" be considered interchangeable with the word "doctor" or "physician" on OTC foot care product labeling. Schering markets Lotrimin AF Antifungal and Tinactin preparations for athlete's foot and Duofilm wart treatment...
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning